- Home
- FRME vs SLS Comparison
FRME vs SLS Comparison
Compare FRME & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRME | SLS |
|---|---|---|
| Founded | 1893 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2004 | 2007 |
Fundamental Metrics
Financial Performance| Metric | FRME | SLS |
|---|---|---|
| Price | $41.16 | $8.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $46.33 | $32.50 |
| AVG Volume (30 Days) | 400.8K | ★ 6.7M |
| Earning Date | 10-21-2026 | 11-16-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | 13.78 | ★ 50.00 |
| EPS | ★ 2.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.23 | N/A |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | $18.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.66 | $1.39 |
| 52 Week High | $45.33 | $15.88 |
Technical Indicators
Market Signals| Indicator | FRME | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 58.25 | 36.90 |
| Support Level | $40.84 | $4.09 |
| Resistance Level | $41.77 | $9.51 |
| Average True Range (ATR) | 0.67 | 1.09 |
| MACD | 0.20 | -0.25 |
| Stochastic Oscillator | 85.31 | 14.90 |
Price Performance
Historical ComparisonAbout FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment, which is community banking.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.